Add Trial
Sign In

Checkmate 816 / CA209-816 - Hosted By


Randomized, Open Label, Phase 3 Trial of Neoadjuvant Nivolumab and Ipilimumab Plus Chemotherapy Versus Platinum Doublet Chemotherapy Alone in Early Stage NSCLC


Study Type Treatment
Sponsor Name BMS
Disease type Non-Small Cell Lung Cancer
Disease Stage IB – IIIA
Clinical Status Neoadjuvant
Phase III
Intervention / Treatment Nivolumab and Ipilimumab + Chemotherapy versus Chemotherapy Alone
Research Site McGill University Health Center
Investigator Dre Jonathan Spicer
Coordinator Nicolas Raby
Telephone number
Fax number
Study start date December 20, 2016
Study end date November 06, 2018
Trial Status Recruiting
Study Type Treatment
Sponsor Name
Tumor Site NSCLC - Non Small Cell Lung Cancer
Disease Stage Stage I, Stage II, Stage III
Clinical Status Neo-Adjuvant, Operable
Phase Phase I
Intervention / Treatment
Research Site Montreal, QC, McGill University Health Center, Montreal University Hospital Center
Telephone Number +1 (514) 934-4411
Fax Number
Study Start Date
Study End Date
Trial Status


Working Hours :

Now Closed UTC - 4
  • MondayDay Off
  • TuesdayDay Off
  • WednesdayDay Off
  • ThursdayDay Off
  • FridayDay Off
  • SaturdayDay Off
  • SundayDay Off

Price / Claim :

Recruit a patient:

*for confidentiality, do not include the name of the patient

*pour raisons de confidentialité, n'incluez pas le nom du patient

Hosted by :

Claim listing: Checkmate 816 / CA209-816

Our website is under development. We're sorry for any inconvenience that might appear.Notre site web est en cours de développement. Nous sommes désolés pour tout inconvénient qui pourrait survenir.

Reply to Message


Account details will be confirmed via email.

Reset Your Password